EGFR expression in advanced head and neck cutaneous squamous cell carcinoma
Article first published online: 7 JUL 2011
Copyright © 2011 Wiley Periodicals, Inc.
Head & Neck
Volume 34, Issue 5, pages 681–686, May 2012
How to Cite
Sweeny, L., Dean, N. R., Magnuson, J. S., Carroll, W. R., Helman, E. E., Hyde, S. O., Desmond, R. L. and Rosenthal, E. L. (2012), EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck, 34: 681–686. doi: 10.1002/hed.21802
- Issue published online: 6 APR 2012
- Article first published online: 7 JUL 2011
- Manuscript Accepted: 16 MAR 2011
- National Cancer Institute. Grant Numbers: R01 CA142637-01 and, 2T32 CA091078-06
- cutaneous squamous cell carcinoma;
- head and neck;
- nonmelanoma skin cancer;
- epidermal growth factor receptor
The significance of epidermal growth factor receptor (EGFR) expression in advanced cutaneous squamous cell carcinoma (SCC) of the head and neck remains poorly understood.
We performed a retrospective review of patients with advanced-stage (stage III or stage IV) cutaneous SCC of the head and neck (n = 56).
The majority of patients (91%) had stage III disease, with 54% having regional metastasis and 9% with distant metastasis. Two-year survival was 64% and the 5-year survival was 56%. EGFR was found to be overexpressed in 56% of primary tumors and 58% of regional metastatic disease. Overall survival did not correlate with EGFR (p = .47) expression in primary lesions, nor was it associated with an increase in regional (p = .74) or distant metastasis (p = .56). Furthermore, there was no correlation between clinicopathologic characteristics and EGFR expression
These data do not suggest upregulation of EGFR is associated with poor survival or aggressive disease. © 2011 Wiley Periodicals, Inc. Head Neck, 2012